Clinical trials: Moderate-to-severe Psoriasis
Psoriasis
Risankizumab Therapy Versus Placebo for Subjects With Psoriasis in the Russian Federation
The purpose of this study is to assess the safety and efficacy of risankizumab compared to placebo in subjects with moderate to severe chronic plaque psoriasis in the Russian Federation.
- Trial name
- IMMPRESS (NCT03518047)
- Testing
- risankizumab
- Where
- 6 sites in Russia
- Volunteers
- 50 people
- Sponsor
- AbbVie
Psoriasis
Combination of Sotyktu and Enstilar for Plaque Psoriasis
combination deucravacitinib and enstilar foam
- Trial name
- NCT06329258
- Testing
- Enstilar, Deucravacitinib
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Psoriasis Treatment Center of Central New Jersey
Palmo-plantar Psoriasis
Apremilast in Palmo-Plantar Psoriasis
This study will compare the safety and efficacy of Apremilast 30mg to placebo in subjects with moderate to severe plaque psoriasis involving palms and/or soles.
- Trial name
- NCT02400749
- Testing
- Apremilast
- Where
- 11 sites in United States, Canada
- Volunteers
- 100 people
- Sponsor
- Innovaderm Research Inc.
Psoriasis
Study to Assess Change in Disease Symptoms in Adult Participants With Moderate to Severe Psoriasis Treated With Subcutaneous Risankizumab Injection According to Standard of Care
Psoriasis is a chronic inflammatory skin condition that is characterized by symptoms such as pain, itching and discomfort. This can have severe impact on the quality of life including depression, embarrassment, and social…
- Trial name
- prIMMa (NCT04780516)
- Where
- 11 sites in Israel
- Volunteers
- 141 people
- Sponsor
- AbbVie
Moderate to Severe Chronic Plaque Psoriasis
A Clinical Study to Evaluate the Efficacy and Safety of Subcutaneous JS005 Injection in the Treatment of Adults With Moderate to Severe Chronic Plaque Psoriasis
This is a multicenter, randomized, double-blind, parallel, placebo-controlled Phase III clinical study to evaluate the efficacy and safety of JS005 in 702 adult patients with moderate-to-severe chronic plaque psoriasis
- Trial name
- NCT05975268
- Testing
- JS005 (recombinant humanized monoclonal antibody against IL-17A)
- Where
- 63 sites in China
- Volunteers
- 747 people
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
Psoriasis
A Study to Evaluate the Switch From Etanercept to Infliximab in Subjects With Moderate-to-Severe Psoriasis (Study P05133)
This study will evaluate the efficacy, tolerability, and effect on the quality of life of infliximab in adults with moderate-to-severe psoriasis who are resistant to etanercept after 12 weeks of treatment or have failed 24 weeks…
- Trial name
- TANGO (NCT00686595)
- Testing
- Infliximab
- Volunteers
- 48 people
- Sponsor
- Merck Sharp & Dohme LLC
Psoriasis, Moderate to Severe Plaque Psoriasis
A Study to Compare SB17 (Proposed Ustekinumab Biosimilar) to Stelara® in Subject With Moderate to Severe Plaque Psoriasis
This is a randomised, double-blind, multicentre clinical study to evaluate the efficacy, safety, tolerability, PK, and immunogenicity of SB17 compared to Stelara® in subjects with moderate to severe plaque psoriasis.
- Trial name
- NCT04967508
- Testing
- Stelara® (Ustekinumab), SB17 (Proposed Ustekinumab Biosimilar)
- Where
- 32 sites in Czechia, Estonia and 6 more
- Volunteers
- 503 people
- Sponsor
- Samsung Bioepis Co., Ltd.
Chronic Plaque Psoriasis
Adalimumab in Combination With Topical Treatment (Calcipotriol/Betamethasone) in Subjects With Moderate to Severe Psoriasis and Insufficient Response to Classic Systemic Treatment
The objective of this study is to assess the efficacy and safety of adalimumab in combination with topical psoriasis treatment, calcipotriol/betamethasone, vs.
- Trial name
- BELIEVE (NCT00574249)
- Testing
- adalimumab, Calcipotriol/Betamethasone Ointment
- Where
- 131 sites in Austria, Belgium and 13 more
- Volunteers
- 730 people
- Sponsor
- Abbott
Moderate Chronic Plaque Psoriasis, Severe Chronic Plaque Psoriasis
Hulio Interchangeability to Humira®, Comparing Pharmacokinetics, Efficacy, Safety and Immunogenicity
Hulio is a monoclonal antibody currently approved as a biosimilar to European Union approved and United States (US)-Licensed Humira.
- Trial name
- NCT05637515
- Testing
- Humira 40 MG in Prefilled Syringe, Hulio 40 MG in Prefilled Syringe / Humira 40 MG in Prefilled Syringe
- Where
- 36 sites in Bulgaria, Czechia and 2 more
- Volunteers
- 374 people
- Sponsor
- Biocon Biologics Inc.
Psoriasis
Double-Blind, Randomized, Placebo-controlled Comparison of CC-10004 in Subjects With Moderate to Severe Plaque Type Psoriasis
There is an unmet medical need for safe, effective oral therapy for moderate-to-severe psoriasis. CC-10004 will be evaluated in a controlled setting of a clinical study.
- Trial name
- PSOR-003 (NCT00606450)
- Testing
- CC-10004
- Where
- 31 sites in Canada, Czechia and 1 more
- Volunteers
- 260 people
- Sponsor
- Amgen
Psoriasis
A Study to Assess the Efficacy of Risankizumab Compared to FUMADERM® in Subjects With Moderate to Severe Plaque Psoriasis Who Are Naïve to and Candidates for Systemic Therapy
The purpose of this study is to compare the efficacy and safety of subcutaneous (SC) risankizumab and oral FUMADERM provided as study medication in participants with moderate to severe plaque psoriasis who are naïve to and…
- Trial name
- NCT03255382
- Testing
- Fumaderm, risankizumab
- Where
- 23 sites in Germany
- Volunteers
- 120 people
- Sponsor
- AbbVie
Psoriasis
Safety and Efficacy of IDP-122 Lotion When Applied Topically to Subjects With Moderate to Severe Plaque Psoriasis
A Phase 2, Multi-Center, Double-Blind, Randomized, Vehicle-Controlled Study.
- Trial name
- NCT02785185
- Testing
- IDP-122 Vehicle Lotion, IDP-122 Vehicle Cream, IDP-122 Lotion
- Where
- 13 sites in United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Bausch Health Americas, Inc.
Plaque Psoriasis
A Study of Ixekizumab (LY2439821) Compared to Guselkumab in Participants With Moderate-to-Severe Plaque Psoriasis
The purpose of this study is to compare the efficacy and safety of ixekizumab to guselkumab in participants with moderate-to-severe plaque psoriasis.
- Trial name
- IXORA-R (NCT03573323)
- Testing
- Ixekizumab, Guselkumab
- Where
- 124 sites in United States, Canada and 1 more
- Volunteers
- 1,027 people
- Sponsor
- Eli Lilly and Company
Moderate to Severe Plaque Psoriasis
A Phase III Study of SYHX1901 Tablets in the Treatment of Moderate to Severe Plaque Psoriasis
The purpose of this study is to evaluate the efficacy and safety of different doses of SYHX1901 tablets in the treatment of moderate to severe plaque psoriasis.
- Trial name
- NCT06943950
- Testing
- SYHX1901
- Volunteers
- 500 people
- Sponsor
- CSPC Ouyi Pharmaceutical Co., Ltd.
Psoriasis Vulgaris
Dermatologic Research Evaluation and Monitoring of Sleep in Moderate-to-Severe Psoriasis
Getting enough sleep is important for maximizing health and well-being. When it comes to health, sleep is as vital as regular exercise and eating a balanced diet.
- Trial name
- DREAMS-PSO (NCT05102474)
- Testing
- Polysomnography (PSG)
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Palmoplantar Pustulosis
Apremilast in Patients With Moderate to Severe Palmoplantar Pustulosis (PPP) (APLANTUS)
Multicenter, open-label, single-arm, phase II, pilot study. The screening period was up to 4 weeks and treatment took place over 20 weeks per patient.
- Trial name
- APLANTUS (NCT04572997)
- Testing
- Apremilast
- Where
- 5 sites in Germany
- Volunteers
- 21 people
- Sponsor
- Kristian Reich
Psoriasis
Study Evaluating the Safety and Efficacy of Etanercept 50 mg Once Weekly in Subjects With Psoriasis
The primary objective is to assess the efficacy and safety of etanercept 50 mg administered once weekly in subjects with psoriasis over 12 weeks.
- Trial name
- NCT00333034
- Testing
- Etanercept
- Where
- 23 sites in Austria, Belgium and 8 more
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Plaque-type Psoriasis
Efficacy and Safety of Intravenous and Subcutaneous Secukinumab in Moderate to Severe Chronic Plaque-type Psoriasis
The study will assess the safety and efficacy of intravenous (10mg/kg) and subcutaneous (300mg) secukinumab in moderate to severe chronic plaque-type psoriasis who are partial responders to secukinumab.
- Trial name
- STATURE (NCT01412944)
- Testing
- secukinumab 150mg, secukinumab 10mg/kg i.v. regimen
- Where
- 27 sites in United States, Austria and 6 more
- Volunteers
- 43 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Plaque Psoriasis
A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Adult Patients With Chronic Plaque Psoriasis
This is a study to assess the long-term safety, tolerability, and efficacy of bimekizumab.
- Trial name
- NCT03230292
- Testing
- Bimekizumab
- Where
- 10 sites in United States, Australia and 2 more
- Volunteers
- 43 people
- Sponsor
- UCB Biopharma SRL
Plaque Psoriasis
Study of Efficacy and Safety of Secukinumab in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis
The purpose of this study was to determine if secukinumab is effective and safe in the treatment of plaque type psoriasis
- Trial name
- NCT03066609
- Testing
- Secukinumab 150 mg s.c., Secukinumab 300 mg s.c.
- Where
- 32 sites in China, Hungary and 4 more
- Volunteers
- 543 people
- Sponsor
- Novartis Pharmaceuticals